Diffuse systemic sclerosis carries a high morbidity and mortality. The Prospective Registry of
Early Systemic Sclerosis (PRESS), a multicentre incident cohort study of patients with early …

Objective T cells play a key role in the pathogenesis of early systemic sclerosis. This study
was undertaken to assess the safety and efficacy of abatacept in patients with diffuse …

Objective. To assess whether serum concentrations of surfactant protein D (SP-D) and Krebs
von den Lungen-6 (KL-6), glycoproteins expressed by type II pneumocytes, correlate with …

… Faye N Hant8, … sequencing in these GENISOS samples (n=55) and matched HCs (n=33)
for the present study in order to avoid heterogeneity resulting from methodological differences. …

A 57-year-old white woman presents to your office with a 3-to 4-year history of progressive
dyspnea on exertion. Her dyspnea occurs with walking up 1 flight of stairs. She has a cough …

Glucocorticoids, proton pump inhibitors, selective serotonin reuptake inhibitors (SSRIs),
certain antiepileptic drugs, and aromatase inhibitors have significant adverse effects on bone. …

Objective To investigate the relationship between Krebs von den Lungen 6 ( KL ‐6) and CCL
18 levels and the severity and progression of systemic sclerosis ( SS c)–related interstitial …

Objective Interstitial lung disease (ILD) is the leading cause of death in patients with systemic
sclerosis (SSc). Although pulmonary function tests (PFTs) are commonly used to screen for …

Background Abatacept was well tolerated by patients with early diffuse cutaneous systemic
sclerosis in a phase 2, double-blind randomised trial, with potential efficacy at 12 months. We …

Objective Response to immunosuppression is highly variable in systemic sclerosis (SSc)–related
interstitial lung disease (ILD). This study was undertaken to determine whether a …